Analytical Data
-
基因名
HACE1
- Application
-
别名
HACE1; E3 ubiquitin-protein ligase HACE1; HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase 1; HECT-type E3 ubiquitin transferase HACE1
-
种属
Human
-
表达系统
E. coli
-
标签
N-6*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8IYU2
-
表达区间
E2-A909
-
蛋白长度
Partial
-
分子量
104.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HACE1 (HECT domain and ankyrin repeat-containing protein 1) is an E3 ubiquitin ligase that plays a crucial role in various cellular processes, including protein degradation, cell proliferation, and apoptosis. Research into HACE1 has gained momentum due to its involvement in tumorigenesis and cancer progression, particularly in the context of human malignancies. Studies have indicated that HACE1 functions as a tumor suppressor; its downregulation or loss of function is often correlated with aggressive cancer phenotypes. Moreover, HACE1 has been implicated in the regulation of the immune response and inflammatory pathways, further linking it to diseases beyond cancer. The understanding of HACE1’s mechanisms presents potential therapeutic avenues, particularly in enhancing cancer treatments or modulating immune responses. The recombinant expression of HACE1 protein allows for detailed investigations into its biochemical functions, interactions, and structural properties, facilitating the development of targeted strategies for disease intervention. Thus, ongoing research into HACE1 recombinant protein not only aids in deciphering its biological roles but also holds promise for innovative therapeutic approaches in oncology and immunology.
